Lung cancer gene therapy trial halted early

NCT ID NCT05062980

Terminated Disease control Sponsor: Genprex, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who had already received treatment. The goal was to see if the combination was safe and could shrink tumors. However, the study was stopped early because not enough people enrolled, so only 5 participants were treated and the second phase never started.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: quaratusugene ozeplasmid (Reqorsa) combined with pembrolizumab
What this could lead to: If successful, this could point toward a new gene therapy option for lung cancer patients who have already tried other treatments.
What could go wrong: The trial was terminated early due to slow enrollment, so results are very limited. It was only in phase 1, testing safety and dosing, so it is far from proving effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
Millennium Oncology

Houston, Texas, 77090, United States
Moffitt Cancer Center - Magnolia Campus

Tampa, Florida, 33612, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
The Valley Hospital - Luckow Pavilion

Paramus, New Jersey, 07652, United States
Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.